Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 1
Submit an article Journal homepage
426
Views
21
CrossRef citations to date
0
Altmetric
CAUSATION AND PREVENTION

Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature

Judd W. MoulDivision of Urologic Surgery and Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA,Correspondence[email protected]
&
Nancy DawsonLombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA
Pages 1-12 | Published online: 31 Jan 2012

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Nicholas Wong, Judy Yan, Diane Ojo, Jason De Melo, Jean-Claude Cutz & Damu Tang. (2014) Changes in PKM2 Associate with Prostate Cancer Progression. Cancer Investigation 32:7, pages 330-338.
Read now
ShrutiA. Apte, DavidA. Cavazos, KaitlinA. Whelan & LindaA. deGraffenried. (2013) A Low Dietary Ratio of Omega-6 to Omega-3 Fatty Acids May Delay Progression of Prostate Cancer. Nutrition and Cancer 65:4, pages 556-562.
Read now
Robert M Taylor & Laurel O Sillerud. (2012) Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. International Journal of Nanomedicine 7, pages 4341-4352.
Read now

Articles from other publishers (18)

Maria D. Jackson, Evelyn Walker & Marshall K. Tulloch-Reid. (2022) Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men. Quality of Life Research 31:12, pages 3391-3401.
Crossref
Jayant K Rane, Amani Chowdhury, William Kinnaird, Gillian Marks & Reena Davda. (2021) Treatment of metastatic hormone‐sensitive prostate cancer. Trends in Urology & Men's Health 12:6, pages 7-10.
Crossref
Petra Vayne-Bossert, Janet Hardy, Helen Skerman, Patsy Yates, Karyn Sullivan & Phillip Good. (2017) Symptom Clusters in Men With Castrate-Resistant Prostate Cancer. Journal of Pain and Symptom Management 54:3, pages e1-e3.
Crossref
S. Salem, M. Komisarenko, N. Timilshina, L. Martin, R. Grewal, S. Alibhai & A. Finelli. (2017) Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. Clinical Oncology 29:9, pages 601-608.
Crossref
F Saad, C Ivanescu, D Phung, Y Loriot, S Abhyankar, T M Beer, B Tombal & S Holmstrom. (2017) Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer and Prostatic Diseases 20:1, pages 110-116.
Crossref
Lesley Fallowfield, Heather Payne & Valerie Jenkins. (2016) Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology 13:10, pages 643-650.
Crossref
CHIACHIEN JAKE WANG, JAMES YING, PAYAL KAPUR, BRYAN WOHLFELD, CLAUS ROEHRBORN & DONG W. NATHAN KIM. (2016) Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report. Oncology Letters 11:1, pages 713-716.
Crossref
S. Schmid, A. Omlin, D. Blum, F. Strasser, S. Gillessen & C. Rothermundt. (2015) Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review. Annals of Oncology 26:11, pages 2221-2247.
Crossref
ZHIYUAN LIN, RUIXIAN PENG, ZHENYU LI, YANG WANG, CHUNHUA LU, YUEMAO SHEN, JIFENG WANG & GUOWEI SHI. (2015) 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. International Journal of Molecular Medicine 36:2, pages 424-432.
Crossref
Michael BrundageMatthew R. SydesWendy R. ParulekarPadraig WardeRichard CowanAndrea BezjakPeter KirkbrideMatthew ParliamentClare MoynihanJean-Paul BaharyMahesh K.B. ParmarKaren SandersBingshu E. ChenMalcolm D. Mason. (2015) Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. Journal of Clinical Oncology 33:19, pages 2151-2157.
Crossref
Jifeng Wang, Zhenyu Li, Zhiyuan Lin, Baobing Zhao, Yang Wang, Ruixian Peng, Meifang Wang, Chunhua Lu, Guowei Shi & Yuemao Shen. (2015) 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation. Cancer Letters 362:1, pages 83-96.
Crossref
Yohann Loriot, Kurt Miller, Cora N Sternberg, Karim Fizazi, Johann S De Bono, Simon Chowdhury, Celestia S Higano, Sarah Noonberg, Stefan Holmstrom, Harry Mansbach, Frank G Perabo, De Phung, Cristina Ivanescu, Konstantina Skaltsa, Tomasz M Beer & Bertrand Tombal. (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. The Lancet Oncology 16:5, pages 509-521.
Crossref
Jonathan Bergman & Aaron Laviana. (2014) Quality-of-life assessment tools for men with prostate cancer. Nature Reviews Urology 11:6, pages 352-359.
Crossref
Chun-Te Wu, Yu-Jia Chang, Miao-Fen Chen, Jun-Jen Liu, Po-Li Wei, Weu Wang & Hui-Hsiung Liu. (2014) Thrombomodulin mediates the migratory ability of hormone-independent prostate cancer cells through the regulation of epithelial-to-mesenchymal transition biomarkers. Tumor Biology 35:6, pages 6047-6054.
Crossref
Digant Gupta, Donald P Braun & Edgar D Staren. (2013) Prognostic value of changes in quality of life scores in prostate cancer. BMC Urology 13:1.
Crossref
Stephen Harland, John Staffurth, Arturo Molina, Yanni Hao, Dennis D. Gagnon, Cora N. Sternberg, David Cella, Karim Fizazi, Christopher J. Logothetis, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono & Howard I. Scher. (2013) Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer 49:17, pages 3648-3657.
Crossref
Ethan Basch, Karen Autio, Charles J Ryan, Peter Mulders, Neal Shore, Thian Kheoh, Karim Fizazi, Christopher J Logothetis, Dana Rathkopf, Matthew R Smith, Paul N Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L Meyers, Arturo Molina & Charles Cleeland. (2013) Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology 14:12, pages 1193-1199.
Crossref
. (2013) Current World Literature. Current Opinion in Urology 23:3, pages 283-292.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.